Is CJC-1295 Legal? FDA, Compounding and WADA Status
CJC-1295's FDA status, compounding rules and anti-doping status, with a dated timeline of every change we track.
- FDA status
- Not approved
- research chemical
- PCAC vote
- Not reviewed
- not on the Jul 2026 PCAC agenda
- WADA
- Prohibited (S2.2.4)
- In and out of competition
Current status
Not FDA approved · research chemicalNo. CJC-1295 is not FDA approved for any use.
| Country | Status | Source |
|---|---|---|
| United States | No approved product foundNo FDA-approved product found: Drugs@FDA (openFDA) search for active ingredient "cjc-1295" returned no matches on 2 Oct 2026. | api.fda.govchecked 2 Oct 2026 |
Timeline
Compounding and research-use sellers
- Category 2 is the FDA's list of bulk substances it flagged as raising significant safety concerns. Compounding pharmacies are not expected to compound from them while they are on it.
- The Pharmacy Compounding Advisory Committee (PCAC) advises the FDA on which substances belong on the 503A bulks list that pharmacies may compound from. Its votes are advice; the FDA decides.
- "Research use only" products are sold outside these rules and are not checked by the FDA for identity, purity or dose.
FDA compounding record: CJC-1295 appears in FDA's table of bulk drug substances previously in category 2 and withdrawn by the nominators. · fda.gov, checked 2 Oct 2026
Sport and drug testing
Prohibited by WADA (S2.2.4)CJC-1295 is named as a GHRH analogue in S2.2.4 (growth hormone releasing factors), prohibited at all times.
Outside the US
Rules differ by country. What each regulator's own records show, with the date we checked:
| Country | Status | Source |
|---|---|---|
| United Kingdom | No approved product foundNo approved product found in an emc (UK SmPC compendium) search for "cjc-1295" on 2 Oct 2026. | medicines.org.ukchecked 2 Oct 2026 |
| Canada | No approved product foundNo product found in a Health Canada Drug Product Database search for ingredient "cjc-1295" on 2 Oct 2026. | health-products.canada.cachecked 2 Oct 2026 |
| Australia | No approved product foundNo approved product found in an ARTG search for "cjc-1295" on 2 Oct 2026. | tga.gov.auchecked 2 Oct 2026 |
| European Union | No centrally authorised EU medicine foundEMA medicines list, searched 2 Oct 2026 | ema.europa.euchecked 2 Oct 2026 |
FDA names two adverse effects for CJC-1295
FDA’s safety-risk entry for CJC-1295 says it has identified serious adverse events associated with the drug, including increased heart rate and a systemic vasodilatory reaction, and calls the clinical data limited.[3]
The entry also cites immunogenicity risk and difficulty characterizing the peptide and its impurities.[3]
In a dose-ranging trial in healthy adults, no serious adverse reactions were reported.[8]
Sport and registers
WADA's list names CJC-1295 among growth hormone-releasing hormone analogues, alongside sermorelin and tesamorelin.[1]
The Health Canada database returns no active-ingredient records for CJC-1295.[5]
The July 2026 advisory committee agenda excerpt lists BPC-157, KPV, TB-500 and MOTS-c, not CJC-1295.[9]
Common questions
Is CJC-1295 FDA approved?
No. Drugs@FDA returns no match for CJC-1295.[2]
Is CJC-1295 legal to buy?
It is not an approved drug. Online sellers label it "for research use only, not for human use"; the FDA sent warning letters to five such sellers on 24 Aug 2026. Whether a pharmacy may compound it depends on its FDA bulk-substance status. Rules differ by country.
Is CJC-1295 banned by WADA?
Yes. Prohibited by WADA (S2.2.4), in and out of competition.
Is CJC-1295 legal?
FDA's 503A page says state-licensed physicians and pharmacists may only compound drug products using bulk drug substances that meet listed conditions.[10]
Is CJC-1295 banned?
In sport, WADA's list names CJC-1295 as a GHRH analogue.[1]
More on CJC-1295
Sources
- 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 2United States: No FDA-approved product found: Drugs@FDA (openFDA) search for active ingredient "cjc-1295" returned no matches on 2 Oct 2026.U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
- 3US compounding: CJC-1295 appears in FDA's table of bulk drug substances previously in category 2 and withdrawn by the nominators.U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
- 4United Kingdom: No approved product found in an emc (UK SmPC compendium) search for "cjc-1295" on 2 Oct 2026.Electronic Medicines Compendium (UK) · 2026medicines.org.ukAccessed 2 Oct 2026
- 5Canada: No product found in a Health Canada Drug Product Database search for ingredient "cjc-1295" on 2 Oct 2026.Health Canada · 2026health-products.canada.caAccessed 2 Oct 2026
- 6Australia: No approved product found in an ARTG search for "cjc-1295" on 2 Oct 2026.Therapeutic Goods Administration (Australia) · 2026tga.gov.auAccessed 2 Oct 2026
- 7EMA medicines export (centrally authorised medicines) (searched 2 Oct 2026)European Medicines Agency · 2026ema.europa.euAccessed 2 Oct 2026
- 8Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.The Journal of clinical endocrinology and metabolism · 2006PMID 16352683Accessed 2 Oct 2026
- 9Official web pageOfficial web page · web page
- 10Official web pageOfficial web page · web page
Found an error? Report a correction.